Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Universidad de Navarra · National and Kapodistrian University of Athens · +27 more institutions
Abstract
Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma.
In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival.
white cells), as compared with 4.6% of those in the control group (P
Citation impact
- FWCI
- 120.39
- Percentile
- 100%
- References
- 32
Authors
24- MΑMeletios Α. DimopoulosCorresponding
Universidad de Navarra, National and Kapodistrian University of Athens, University College London
- AOAlbert Oriol
University College London, Universidad de Navarra, Institut Català d'Oncologia
- HNHareth Nahi
University College London, Universidad de Navarra, Karolinska University Hospital, Karolinska Institutet
- JFJesús F. San Miguel
Navarre Institute of Health Research, Clinica Universidad de Navarra, University College London, Universidad de Navarra
- NJNizar J. Bahlis
Universidad de Navarra, University of Calgary, University College London
Topics & keywords
- Daratumumab
- Lenalidomide
- Dexamethasone
- Multiple myeloma
- Medicine
- Oncology
- Internal medicine
- Good health and well-being